COMMUNIQUÉS West-GlobeNewswire

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
23/12/2025
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational [...]
Glucose Health, Inc. Completes Preferred Stock Conversion at an 85% Premium Positioning Company for Rapid Growth
23/12/2025
BENTONVILLE, Ark., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a consumer-health company specializing in soluble-fiber nutrition products for metabolic support, today announced the completion of [...]
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
23/12/2025
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Avicanna Announces Changes to its Board of Directors
23/12/2025
TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company” ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization [...]
Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests
23/12/2025
- TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA 1 positive operations in Q3 2025 and expects to achieve strong additional [...]
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
23/12/2025
--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “ [...]
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
23/12/2025
NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will [...]
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
23/12/2025
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of [...]
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
23/12/2025
Milestone advances manufacturing readiness and supports long-term commercialization strategy BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: [...]
Cassava Announces Agreement to Settle Securities Class Action Litigation
23/12/2025
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous [...]
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
23/12/2025
Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) [...]
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
23/12/2025
Enters into Cooperation Agreement with Browning West SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company’s Board of [...]
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
23/12/2025
Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented resveratrol-based [...]
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
23/12/2025
PYLCLARI ® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, has announced that [...]
CancerVax Reviews Major Scientific and Strategic Milestones Achieved in 2025
23/12/2025
Year-End Recap Highlights Breakthrough Discoveries, Platform Advancements, and Strengthened Scientific Leadership Lehi, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, December 23, 2025 - CancerVax, Inc., the [...]
Burning Rock Announces Results of 2025 Annual General Meeting
23/12/2025
GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “ Company ” or “ Burning Rock ”), a company focusing on the application of next generation sequencing (NGS) technology [...]
Vireo Growth Inc. Enters California and Florida and Strengthens Delivery Platforms with Acquisition of Eaze Inc.
23/12/2025
Transaction will expand Vireo’s operating footprint to 10 states with 166 dispensaries and approximately 800,000 sq. ft. of cultivation and production Acquisition also will add an incremental 14 dispensaries to Company’ [...]
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
23/12/2025
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first [...]
Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique
23/12/2025
Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants démontrant que le Dupixent a [...]

Pages